Treatment of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19): a systematic review of in vitro, in vivo, and clinical trials

Han, Young Joo and Lee, Keum Hwa and Yoon, Sojung and Nam, Seoung Wan and Ryu, Seohyun and Seong, Dawon and Kim, Jae Seok and Lee, Jun Young and Yang, Jae Won and Lee, Jinhee and Koyanagi, Ai and Hong, Sung Hwi and Dragioti, Elena and Radua, Joaquim and Smith, Lee and Oh, Hans and Ghayda, Ramy A. and Kronbichler, Andreas and Effenberger, Maria and Kresse, Daniela and Denicolò, Sara and Kang, Woosun and Jacob, Louis and Shin, Hanwul and Shin, Jae Il (2021) Treatment of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19): a systematic review of in vitro, in vivo, and clinical trials. Theranostics, 11 (3). pp. 1207-1231. ISSN 1838-7640

Preview	Text Published Version Available under the following license: Creative Commons Attribution. Download (1MB) | Preview
	Text Accepted Version Restricted to Repository staff only Available under the following license: Creative Commons Attribution. Download (755kB) | Request a copy

Abstract

Rationale: Coronavirus disease 2019 (COVID-19) has spread worldwide and poses a threat to humanity. However, no specific therapy has been established for this disease yet. We conducted a systematic review to highlight therapeutic agents that might be effective in treating COVID-19. Methods: We searched Medline, Medrxiv.org, and reference lists of relevant publications to identify articles of in vitro, in vivo, and clinical studies on treatments for severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and COVID-19 published in English until the last update on October 11, 2020. Results: We included 36 studies on SARS, 30 studies on MERS, and 10 meta-analyses on SARS and MERS in this study. Through 12,200 title and 830 full-text screenings for COVID-19, eight in vitro studies, 46 randomized controlled trials (RCTs) on 6,886 patients, and 29 meta-analyses were obtained and investigated. There was no therapeutic agent that consistently resulted in positive outcomes across SARS, MERS, and COVID-19. Remdesivir showed a therapeutic effect for COVID-19 in two RCTs involving the largest number of total participants (n = 1,461). Other therapies that showed an effect in at least two RCTs for COVID-19 were sofosbuvir/daclatasvir (n = 114), colchicine (n = 140), IFN-β1b (n = 193), and convalescent plasma therapy (n = 126). Conclusions: This review provides information to help establish treatment and research directions for COVID-19 based on currently available evidence. Further RCTs are required.

Item Type:	Journal Article
Keywords:	COVID-19, Therapeutic Agent, SARS, MERS, mortality, coronavirus
Faculty:	COVID-19 Research Collection Faculty of Science & Engineering
SWORD Depositor:	Symplectic User
Depositing User:	Symplectic User
Date Deposited:	26 Oct 2020 09:56
Last Modified:	15 Nov 2021 17:10
URI:	https://arro.anglia.ac.uk/id/eprint/706008

Actions (login required)

Edit Item